Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients
- Conditions
- Islets of Langerhans TransplantationDiabetes Mellitus, Type 1Kidney Transplantation
- Interventions
- Registration Number
- NCT01033500
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
The investigators hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory blockade-based immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce the islet mass required to achieve and sustain insulin independence following simultaneous islet-kidney transplantation.
- Detailed Description
This is a single center, open-label, non-randomized, prospective, pilot study of 8 Type 1 diabetic/uremic patients, ages 18-60 undergoing simultaneous islet-kidney transplantation. Study to include both male and/or female subjects.
We hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory blockade-based immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce the islet mass required to achieve and sustain insulin independence following simultaneous islet-kidney transplantation.
Furthermore, we anticipate an improvement in creatinine clearance and a reduction in Interstitial Fibrosis/Tubular Atrophy in the transplanted renal allograft, and a reduction of "de novo" human anti-HLA antibody and auto-antibody formation against the respective donors.
Without calcineurin inhibitors or steroids, we hypothesize that belatacept, in conjunction with sirolimus and mycophenolic acid will provide balanced immunosuppression for combined islet-kidney transplantation.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
-
Subjects will include those with Type 1 Diabetes Mellitus, undergoing kidney transplantation, and:
- are closely followed by a primary care provider and/or endocrinologist for >6 months prior to enrollment in the trial
- do not have psychogenic factors which preclude therapeutic compliance
- have a fasting C-peptide of <0.2 ng/mL• have diabetes for >5 years • are between 18 and 65 years of age
- have a creatinine clearance of less than 20 mL/min
- have a body mass index of less than or equal to 28
- In the case of women of childbearing potential (WOCBP), must have a negative pregnancy test and avoid pregnancy throughout the study and 8 weeks after final dose of study drug.
- WOCBP must use two adequate methods of contraception.
- A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for up to 8 weeks after the last dose of study drug to minimize the risk of pregnancy.
-
Untreated proliferative diabetic retinopathy
- HgbA1C >12
- creatinine clearance > 20 ml/minute
- presence of panel reactive antibodies (PRA) >20% (per CDC-based assay)
- malignancy or previous malignancy, except for adequately treated skin cancers (basal cell or squamous cell carcinoma) within the past 5 years
- sensitivity to iodine and/or shellfish (re: Iothalamate-based GFR testing)
- x-ray evidence of pulmonary infection
- active infections
- active peptic ulcer disease, gall stones, hemangioma, cirrhosis or portal hypertension
- serological evidence of HIV, HBSAg or HCV
- abnormal liver function tests (elevated AST and ALT > 2x upper limit of normal)
- anemia (hemoglobin) <9 gm/dl
- serum triglycerides >200 mg/dl
- serum cholesterol >240 mg/dl
- body mass index above 28
- unstable cardiovascular status (including positive stress echocardiography if >age 35); severe coexisting cardiac disease, myocardial infarction within the 6 months prior to enrollment in the study, left ventricular ejection fraction of <30%, or evidence of ongoing ischemia
- prostate specific antigen (PSA) >4 in males >40 years old or with family history of prostate cancer
- pregnancy or breastfeeding
- sexually-active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable)
- alcohol abuse, substance abuse or smoking within the previous 6 months
- insulin requirement >1.5 u/kg/day
- negative for Epstein-Barr virus by IgG determination
- history of factor V deficiency
- acute or chronic pancreatitis
- recurrent attenuated vaccine(s) within the previous 2 months
- use of an investigational agent within the past 4 weeks
- sexually active, fertile men not using effective birth control, if their partners are WOCBP
- prisoners, or subjects who are involuntarily incarcerated
- subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
- Previous kidney transplant or previous non-renal transplant
- kidney transplant from expanded criteria donor (ECD)
- kidney cold ischemic time projected to be > 20 hours
- currently receiving immunosuppressive agents for autoimmune disease or other conditions or have comorbidities that treatment with such agents are likely during the trial
- any condition or circumstance that makes it unsafe to undergo an islet cell or kidney transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SIK Belatacept Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
- Primary Outcome Measures
Name Time Method Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year. 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Wisconsin
🇺🇸Madison, Wisconsin, United States